Damien Hirst, Valium (2000)
Buy the entire asset
Request to purchase the entire asset instead of just fractions.
Main reasons to invest
Return Potential: An investment of €500 could reach an estimated value of €792 in 5 years.
Cost-to-Return Ratio: With just 8.7% entry fees for platform, storage, insurance and handling, your profit could be 73.2% (58.5% net after fee).
Iconic Series: Damien Hirst’s pharmaceutical series benefits from strong collector demand and institutional recognition, supported by secondary-market liquidity and a projected total net return of 58.5% over 5 years.
Description
- 5 Year Horizon: Planned exit in 2031 to capture continued demand for Damien Hirst's iconic pharmaceutical series and sustained collector interest in editioned works from blue-chip artists.
- 58.5% Total Net ROI. (Balanced): Based on a probability-weighted scenario using recent market performance of Hirst prints and comparable editioned works within his pharmaceutical series.
- -0.8% discount prior to fees: Entry pricing reflects current market positioning after fees, supported by strong historical performance (44.7% CAGR from 10/2023 to 04/2025) and robust secondary market liquidity.
- Sharpe Ratio of 0.89: Indicates an attractive risk-adjusted return profile that exceeds the SMI's five-year benchmark of 0.6, reflecting well-balanced returns relative to expected volatility.
- Standard Deviation (20.0%): Reflects moderate volatility typical of editioned prints from established contemporary artists, with liquidity supported by regular market turnover.
- Market Comparables: The investment case is anchored by 9 main comparable sales, providing a solid foundation for valuation and demonstrating consistent market activity for similar works.
Damien Hirst's Valium (2000) is a defining work from one of the most recognizable and conceptually charged series in contemporary art. As part of Hirst's iconic pharmaceutical series, this print embodies the visual and thematic language that established him as a leading figure of the Young British Artists movement and a blue-chip name in the global art market.
What makes this piece especially compelling is its position within a body of work that has demonstrated consistent collector demand and institutional validation. The pharmaceutical series remains one of Hirst's most sought-after themes, offering both visual immediacy and conceptual depth that resonates across collector segments.
The editioned format supports regular market turnover and ongoing price discovery, making it easier to enter and exit positions compared to unique works. This structure has historically contributed to tighter bid-ask spreads and sustained liquidity, a critical factor for investors seeking both growth potential and flexibility.
For investors, the appeal lies in the combination of blue-chip artist pedigree, signature series recognition, verified market pricing, and institutional backing. With a Sharpe ratio of 0.9, this piece offers exposure to a market-leading contemporary artist with a proven track record and enduring relevance.
Expert
The art investment advisors of Maddox bring together years of specialist knowledge and practical experience with objective market analysis to offer their clients quality advice and consistent returns.
